1. Home
  2. FMN vs ACRV Comparison

FMN vs ACRV Comparison

Compare FMN & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Federated Hermes Premier Municipal Income Fund

FMN

Federated Hermes Premier Municipal Income Fund

HOLD

Current Price

$11.09

Market Cap

87.0M

Sector

Finance

ML Signal

HOLD

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$2.21

Market Cap

74.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FMN
ACRV
Founded
2002
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
87.0M
74.0M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
FMN
ACRV
Price
$11.09
$2.21
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$11.67
AVG Volume (30 Days)
23.8K
382.5K
Earning Date
01-01-0001
05-08-2026
Dividend Yield
3.86%
N/A
EPS Growth
N/A
15.13
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$568.17
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.56
$1.27
52 Week High
$11.76
$3.56

Technical Indicators

Market Signals
Indicator
FMN
ACRV
Relative Strength Index (RSI) 43.47 70.10
Support Level $11.02 $2.14
Resistance Level $11.32 $2.48
Average True Range (ATR) 0.14 0.12
MACD 0.00 0.07
Stochastic Oscillator 33.59 84.58

Price Performance

Historical Comparison
FMN
ACRV

About FMN Federated Hermes Premier Municipal Income Fund

Federated Hermes Premier Municipal Income Fund is a United States-based diversified, closed-end management investment company. The investment objective of the fund is to provide current income exempt from federal income tax, including the federal alternative minimum tax by investing in long-term, tax exempt municipal bonds diversified among states, sectors and issuers. Its portfolio of investments comprises different sectors such as hospitals, toll road, senior care, airport, tobacco, and other sectors.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

Share on Social Networks: